Granted Patent B2

US 9,192,651 · App. 13/791,921 · Granted Nov 24, 2015

Inventors: Tirtha Chakraborty (Medford, MA); Antonin de Fougerolles (Brookline, MA)

Assignee: Moderna Therapeutics, Inc.

A61K38/177A61K9/1271A61K31/7115A61K38/17A61K38/45A61K48/005A61K48/0033A61K48/0066C07K14/005C07K14/435C07K14/47C07K14/4705C07K14/4713C07K14/485C07K14/505C07K14/535C07K14/62C07K14/705C12N9/1051C12N9/16C12N9/2402C12N9/2445C12N9/6451C12N9/88C12N9/93C12N15/11C12N15/52C12N15/85C12N15/87C12P13/04C12P21/00A61K38/00

Abstract

Claims (10)

1. An isolated polynucleotide which is an mRNA, said mRNA comprising:

a first region of linked nucleosides, said first region encoding SEQ ID NO: 2626 and said first region having at least 85% identity to SEQ ID NO: 15265.

2. A pharmaceutical composition comprising the isolated polynucleotide of claim 1 and a pharmaceutically acceptable excipient.

3. The pharmaceutical composition of claim 2 , wherein the excipient is lipid nanoparticle.

4. The isolated polynucleotide of claim 1 , wherein the mRNA comprises at least one untranslated region 5′ relative to the first region and at least one untranslated region 3′ relative to the first region.

5. The isolated polynucleotide of claim 4 , wherein the 5′ untranslated region is heterologous to the first region of the mRNA.

6. The isolated polynucleotide of claim 4 , wherein the 3′ untranslated region is heterologous to the first region of the mRNA.

7. The isolated polynucleotide of claim 4 , wherein the 5′ untranslated region and the 3′ untranslated region are heterologous to the first region of the mRNA.

8. The isolated polynucleotide of claim 4 , wherein the mRNA comprises at least two stop codons.

9. The isolated polynucleotide of claim 1 , wherein the coding region is selected from the group consisting of SEQ ID NO: 15265, 15319 and 15420.

Assignments (11)

Continuity (52)